Trump's Order to Fast-Track Psychedelics

Trump's Psychedelics Order Fast-Tracks Psilocybin First

Trump's April 2026 executive order directs the FDA to fast-track psychedelic drugs. Ibogaine got the headlines — psilocybin will get the approval.

President Donald Trump's April 18, 2026 executive order on psychedelics was staged as an ibogaine event — Joe Rogan in the Oval Office, a former Navy SEAL behind the desk, a text-message origin story about a West African shrub. The order's operative machinery points somewhere else. By instructing the FDA to hand its new Commissioner's National Priority Vouchers to breakthrough-designated psychedelics, Trump has cleared a runway that Compass Pathways' synthetic psilocybin — not ibogaine — is positioned to land on first. The real winner of "Trump's psychedelics order" is a British-listed biotech whose Phase 3 depression data landed two months before the signing ceremony.

What the order actually does

Executive Order 14401, formally titled "Accelerating Medical Treatments for Serious Mental Illness", commits four discrete instruments. It directs the FDA to issue Commissioner's National Priority Vouchers (CNPVs) to psychedelics that already hold Breakthrough Therapy designation. It orders the FDA and DEA to build a Right to Try pathway for terminally ill patients seeking investigational psychedelics, including ibogaine. It obligates HHS to allocate "at least $50 million" from existing ARPA-H funds to match state programs. And it tells the Attorney General to begin rescheduling reviews the moment a Schedule I psychedelic clears Phase 3.

The financial gravity sits in the first instrument. The CNPV program, launched by FDA Commissioner Marty Makary in June 2025, promises 30- to 60-day drug reviews — down from the standard 10 months. According to a Brookings analysis by Ryan Conrad, a comparable acceleration under the older Priority Review Voucher program has commanded resale prices above $150 million per voucher. The order does not name recipients, but Makary told reporters the FDA would issue vouchers to three psychedelics "in the coming weeks," per NPR.

Read the text and the political theater diverges from the drug economics. The order repeatedly names ibogaine. The CNPV eligibility criterion — breakthrough designation plus a submitted new drug application — filters ibogaine out. There is no active U.S. IND for ibogaine as a marketed therapy. There is one, moving fast, for psilocybin.

Compass Pathways is the drug that fits the door

On February 17, 2026, Compass Pathways reported that its synthetic psilocybin, COMP360, hit its primary endpoint in the first of two Phase 3 trials for treatment-resistant depression, according to The Economist. A second confirmatory readout followed. In the White House release accompanying the executive order, Compass CEO Kabir Nath confirmed the company is "already actively working with the FDA on a rolling submission and review for COMP360 in TRD."

That combination — breakthrough designation, positive Phase 3 data, live submission — is the only door the CNPV opens. Observers cited by Science had expected psilocybin to become the first federally approved psychedelic in 2027. With the voucher, that date compresses. "Approval may now come sooner," AAAS wrote.

MindMed's LSD analog MM120, whose Phase 3 depression trial began in April 2025 per a Nature review of the field, is next in line. Atai Life Sciences' DMT and ibogaine programs sit further back. The company Trump did not mention — Lykos Therapeutics, whose MDMA-PTSD application the FDA rejected on August 9, 2024 and whose Psychopharmacology papers were retracted the same weekend — is now effectively frozen out. Per Science's post-rejection analysis, Lykos still needs another Phase 3 trial. It has no breakthrough submission ready to redeem a voucher.

The ibogaine paradox

Ibogaine dominates the executive order's rhetoric and its symbolism. The BBC reported that of the $50 million federal commitment, the White House earmarks funding specifically for ibogaine research, matching the $50 million Texas allocated in 2025 for clinical trials in opioid use disorder, PTSD and traumatic brain injury. Rep. Morgan Luttrell (R-TX-8), the former Navy SEAL present at the signing, introduced H.R. 9559 on June 30, 2026 to codify the framework.

But the science is thinner than the politics. Al Jazeera noted that the FDA is "taking steps to clear the way for the first-ever human trials of ibogaine in the US" — meaning the compound Trump wants approved has not yet been legally administered in a domestic clinical trial. Peer-reviewed literature is unambiguous about why. A Clinical Toxicology review documented 27 ibogaine-associated fatalities, mostly from ventricular arrhythmias driven by hERG-channel blockade and QT prolongation. A recent case series in Addiction confirmed that cardiac events occur at therapeutic doses in patients without pre-existing conditions.

The most cited efficacy signal — a Nature Medicine study of magnesium-ibogaine therapy in 30 Special Operations veterans — was an open-label observational trial conducted at a private clinic in Mexico. The Stanford investigators explicitly noted: "no investigational new drug application with the US FDA was required." The regulatory scaffolding the executive order relies on does not yet exist for ibogaine. It exists, and works, for psilocybin.

Alan Davis, who directs Ohio State's Center for Psychedelic Drug Research and Education, put it flatly to NPR: other psychedelics have "much stronger data showing they're safe and they work." His recent psilocybin-PTSD trial produced 75% remission in veterans. Ibogaine's role in the executive order is doing political work — signaling to the MAHA base, giving Rogan a win, throwing a bone to Texas's Republican patrons of the compound including former Governor Rick Perry — while psilocybin does the regulatory work.

The MAHA fault line

The order is also a boundary marker inside Trump's own coalition. Former FDA Commissioner Scott Gottlieb argued in an AEI op-ed that the executive order "pairs faster drug development with continued FDA oversight" — a rebuke, he wrote, to voices in the Make America Healthy Again movement who "don't simply want psychedelic compounds reviewed through traditional means; they want aspects of the approval process dismantled entirely."

That tension runs through HHS Secretary Robert F. Kennedy Jr.'s tenure. Kennedy has spent much of 2025 loosening FDA vaccine standards while tightening COVID-19 shot reviews, a posture that has bled institutional credibility from the same agency now being asked to fast-track Schedule I compounds. Kennedy has framed psychedelics as a top MAHA priority. NPR's Will Stone reported that Kennedy's "war on public health" social-media post listed psychedelics first among suppressed therapies.

Gottlieb's model — accelerated review, retained gatekeeping — is the establishment version of the deal. The MAHA version would push further: Right to Try as end-run, rescheduling before Phase 3 completion, direct veteran access to Mexican-style ibogaine clinics. The executive order's Section 5 — which orders rescheduling review only after successful Phase 3 completion — sits on the establishment side of that line. For now.

Second-order effects worth watching

Three consequences deserve tracking beyond the drug approvals themselves.

First, valuation. Compass Pathways and MindMed shares moved sharply on the announcement, per NPR reporting. Under rare pediatric PRV precedent codified at 21 U.S.C. §360ff, vouchers have sold for $67–$350 million, with 17 of 31 awarded through 2019 resold to other sponsors, per a Government Accountability Office report. If CNPVs prove transferable, a psilocybin voucher becomes a portable financial asset — and the psychedelic sector suddenly has a hard-currency exit for early-stage capital.

Second, state-federal architecture. The $50 million ARPA-H allocation matches — dollar for dollar — what Texas already committed. That is not a coincidence. It signals a template: red-state legislatures build psychedelic infrastructure; the federal government backstops it. Kentucky's flirtation with using opioid settlement money for ibogaine research, killed in 2024 per NPR, may look different with federal matching funds on the table.

Third, VA data flows. Section 4 orders HHS, FDA and the Department of Veterans Affairs to sign data-sharing memoranda covering psychedelic clinical trials — five of which the VA is already participating in across New York, California and Oregon, per NPR. The regulatory value is that real-world VA evidence can substitute for expensive confirmatory trials. The political value is that veterans become the moral warrant for expanding indications well beyond PTSD.

What to watch next

• Late July–August 2026: First public list of CNPV recipients. If Compass's COMP360 psilocybin is named, expect a PDUFA action date by early 2027.
• September 2026: ARPA-H publishes matching-fund criteria for state programs. Texas's ibogaine consortium is the reference case; Oregon and Colorado will move next.
• H2 2026: DEA response to Section 5. The Attorney General's office must show a rescheduling pathway ready to activate on FDA approval; failure to do so would leave the first approved psychedelic in the same legal purgatory that has trapped medical marijuana.
• Q4 2026: First FDA-authorized U.S. clinical trial of ibogaine. Al Jazeera reported preparatory work is underway; a cardiac-safety-focused Phase 1 is the plausible entry point.
• H.R. 9559: Luttrell's bill goes to Energy and Commerce. Bipartisan uptake — Democratic co-sponsors would extend the political durability of the framework past this administration.

Diplomat View

The falsifiable call: within 18 months, the FDA will approve Compass Pathways' COMP360 psilocybin for treatment-resistant depression as the first federally licensed psychedelic in U.S. history, and it will do so through the exact CNPV mechanism Trump's April order activated — while ibogaine, the compound the order most loudly celebrated, will still not have completed a single domestic Phase 3 trial. The order is best read not as an ibogaine breakthrough but as a psilocybin fast-lane wearing an ibogaine costume. Two conditions would revise the forecast: a torsades-related death in an early U.S. ibogaine trial that spooks the FDA off the entire class, or a Kennedy-driven rescheduling shortcut that bypasses Section 5's Phase 3 gate and hands MAHA the win Gottlieb warned against. Absent those, the winner of Trump's psychedelics order is a public-benefit British biotech, four million treatment-resistant depression patients, and — later — the veterans whose suffering supplied the political capital.

The bottom line: Trump's order is being covered as a MAHA victory for ibogaine. It is, in operative fact, a regulatory subsidy for psilocybin — and the first federally approved psychedelic medicine in American history is now a matter of months, not years, away. Read the executive order's Section 2, not its press release, to see who actually won.